PhRMA and the European Federation of Pharmaceutical Industries and Associations' decision to agree to share more clinical trial data should be a first step in a process leading toward greater transparency, Steve Williams writes. If adhered to, the principles could have a large effect, he writes.

Full Story:

Related Summaries